PHVS
Pharvaris BV
NASDAQ: PHVS · HEALTHCARE · BIOTECHNOLOGY
$30.09
+1.38% today
Updated 2026-05-08
Market cap
$1.97B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.48
Dividend yield
—
52W range
$15 – $31
Volume
0.3M
Pharvaris BV (PHVS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | — | $614.00 | $8436.00 | $80456.00 | $150186.00 | $252271.00 | — | — |
| Gross profit | — | $-614.00 | $-8436.00 | $-80456.00 | $-150186.00 | $-252271.00 | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $3.65M | $6.36M | $22.24M | $35.79M | $57.38M | $65.58M | $98.56M | $124.48M |
| SG&A | $668121.00 | $2.33M | $5.50M | $18.35M | $29.04M | $31.34M | $46.72M | $45.34M |
| Operating income | $-4.31M | $-8.97M | $-28.51M | $-54.14M | $-86.71M | $-96.91M | $-145.69M | $-169.82M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-4.31M | $-8.98M | $-29.71M | $-54.06M | $-86.56M | $-96.66M | $-145.59M | $-169.40M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-4.31M | $-8.98M | $-29.72M | $-54.14M | $-86.71M | $-96.91M | $-145.69M | $-169.82M |
| Interest expense | $0.00 | $4377.00 | $92470.00 | $278181.00 | $16105.00 | $20055.00 | — | — |
| Income tax | $380.00 | $16881.00 | $-94904.00 | $70117.00 | $679087.00 | $1.05M | $1.83M | — |
| Effective tax rate | -0.0% | -0.2% | 0.3% | -0.2% | -0.9% | -1.1% | -1.4% | 0.0% |
| Net income | $-4.31M | $-8.98M | $-29.62M | $-42.73M | $-76.33M | $-100.88M | $-134.22M | $-175.70M |
| Net income growth (YoY) | — | -108.2% | -229.7% | -44.2% | -78.6% | -32.2% | -33.1% | -30.9% |
| Profit margin | — | — | — | — | — | — | — | — |